# PSA and MRI-first prostate cancer screening

Source: https://onco.cc/technologies/prostate-screening-psa-mri/  
OnCo record `prostate-screening-psa-mri` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Whether men should be screened for prostate cancer is still debated; the modern approach uses a PSA blood test followed by an MRI scan, which finds the cancers that matter while leaving harmless ones alone.

## Summary

The European ERSPC trial showed that PSA screening reduces prostate cancer mortality (rate ratio 0.80 at 16 years, with 570 men invited and 18 diagnosed per death averted), while the UK CAP trial of a single PSA test found only a small absolute difference at 15 years (0.69% versus 0.78% prostate cancer deaths). Overdiagnosis of low-grade disease was the price. The Göteborg-2 trial (NEJM 2022) showed that using MRI after an elevated PSA and biopsying only MRI-visible lesions halved the detection of clinically insignificant cancer while missing few significant cancers, and PROBASE in Germany is testing risk-adapted screening from age 45. In the UK, TRANSFORM (Prostate Cancer UK and government funded, opened 2025-26) compares PSA, fast MRI and genetic risk approaches in tens of thousands of men, with at least one in ten Black men, ahead of a decision on a national programme; the UK National Screening Committee has not recommended population screening. The USPSTF gives a grade C (individual decision) for men 55 to 69, and the EU Council in 2022 asked member states to evaluate stepwise PSA-plus-MRI programmes.

## Fields

- Kind: Technology
- Status: emerging
- Last checked: 2026-09-10
- Principle: A PSA threshold selects men for multiparametric or biparametric MRI; only PI-RADS 3-5 lesions are biopsied, with active surveillance for low-grade disease.
- Strengths: MRI-first roughly halves overdiagnosis of insignificant cancer; Mortality benefit of PSA screening is established in ERSPC
- Limitations: MRI capacity and reader variability; Benefit-harm balance still contested by screening committees; Uncertain value in Black men and men with a family history, who are under-represented in trials

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Prostate_cancer_screening
- ERSPC 16-year follow-up (Eur Urol 2019): https://doi.org/10.1016/j.eururo.2019.02.009
- CAP trial 15-year follow-up (JAMA 2024): https://doi.org/10.1001/jama.2024.4011
- Prostate Cancer UK: TRANSFORM trial: https://prostatecanceruk.org/research/transform-trial
- USPSTF prostate cancer screening (2018): https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/prostate-cancer-screening

## Connected records

- terms: [Gleason score / Grade Group](https://onco.cc/terms/gleason-grade-group/), [Lead time, and lead-time bias](https://onco.cc/terms/lead-time-bias/), [Number needed to screen (and number needed to diagnose)](https://onco.cc/terms/number-needed-to-screen/), [Overdiagnosis](https://onco.cc/terms/overdiagnosis/), [Overtreatment](https://onco.cc/terms/overtreatment/), [PI-RADS (Prostate Imaging Reporting and Data System)](https://onco.cc/terms/pi-rads/), [Polygenic risk score (PRS)](https://onco.cc/terms/polygenic-risk-score/), [PSA (prostate-specific antigen)](https://onco.cc/terms/psa/), [Screening](https://onco.cc/terms/screening/), [Template mapping biopsy (transperineal template prostate mapping)](https://onco.cc/terms/template-mapping-biopsy/)
- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Early Detection & Screening](https://onco.cc/fronts/early-detection/), [Imaging](https://onco.cc/fronts/imaging/)
- technologies: [Active surveillance](https://onco.cc/technologies/active-surveillance/), [Multiparametric prostate MRI (PI-RADS)](https://onco.cc/technologies/mp-mri/), [Polygenic risk scores for cancer](https://onco.cc/technologies/polygenic-risk-scores/), [PSMA PET](https://onco.cc/technologies/psma-pet/), [Serum tumour markers: proper use and misuse](https://onco.cc/technologies/serum-tumour-markers/)
- trials: [GÖTEBORG-2 (MRI-based prostate cancer screening)](https://onco.cc/trials/goteborg-2/), [PRECISION](https://onco.cc/trials/precision-mri/), [ProtecT](https://onco.cc/trials/protect/), [TRANSFORM](https://onco.cc/trials/transform-prostate/)
- key papers: [A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer](https://onco.cc/key-papers/paper-hugosson-eur-urol/), [ERSPC: screening and prostate cancer mortality in a randomised European study](https://onco.cc/key-papers/paper-schroder-erspc-screening-mortality-nejm-2009/), [PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer](https://onco.cc/key-papers/paper-ahmed-promis-multiparametric-mri-lancet-2017/), [Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality: A Secondary Analysis of the CAP Randomized Clinical Trial](https://onco.cc/key-papers/paper-martin-jama/)
- ideas: [Judge a prostate screening programme on metastatic presentation, not on incidence or mortality](https://onco.cc/ideas/idea-prostate-metastatic-presentation-as-the-screening-endpoint/), [Publish a per-lesion miss rate for every prostate MRI service before it is allowed to guide focal treatment](https://onco.cc/ideas/idea-prostate-per-lesion-mri-audit-before-focal-treatment/)

---
JSON: https://onco.cc/api/v1/entities/prostate-screening-psa-mri.json